In the last trading session, 2.17 million shares of the FibroGen Inc (NASDAQ:FGEN) were traded, and its beta was 0.70. Most recently the company’s share price was $0.34, and it changed around -$0.03 or -6.57% from the last close, which brings the market valuation of the company to $34.40M. FGEN currently trades at a discount to its 52-week high of $2.93, offering almost -761.76% off that amount. The share price’s 52-week low was $0.33, which indicates that the current value has risen by an impressive 2.94% since then. We note from FibroGen Inc’s average daily trading volume that its 10-day average is 0.59 million shares, with the 3-month average coming to 1.77 million.
FibroGen Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 4.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 2 recommended FGEN as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. FibroGen Inc is expected to report earnings per share of -0.3 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FibroGen Inc (NASDAQ:FGEN) trade information
Instantly FGEN has showed a red trend with a performance of -6.57% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.4120 on recent trading dayincreased the stock’s daily price by 17.48%. The company’s shares are currently down -61.34% year-to-date, but still down -14.22% over the last five days. On the other hand, FibroGen Inc (NASDAQ:FGEN) is -12.15% down in the 30-day period. We can see from the shorts that 4.77 million shares have been sold at a short interest cover period of 3.93 day(s).
The consensus price target as assigned by Wall Street analysts is $28, which translates to bulls needing to increase their stock price by 98.79% from its current value. Analyst projections state that FGEN is forecast to be at a low of $28 and a high of $28.
FibroGen Inc (FGEN) estimates and forecasts
FibroGen Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -78.98 percent over the past six months and at a 65.92% annual growth rate that is well above the industry average of 19.40%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 53.80% in revenue this quarter, and will report an increase of 61.40% in the next quarter. The year-over-year growth rate is expected to be 18.10%, up from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 34.76M in revenue for the current quarter. 2 analysts expect FibroGen Inc to make 33.21M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 40.13M and 27.14M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -13.40%. Forecasts for the next quarter put sales growth at 22.40%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -23.23%.
FGEN Dividends
FibroGen Inc’s next quarterly earnings report is expected to be released in November.
FibroGen Inc (NASDAQ:FGEN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.85% of FibroGen Inc shares, and 56.59% of them are in the hands of institutional investors. The stock currently has a share float of 57.08%. FibroGen Inc stock is held by 124.0 institutions, with PRIMECAP MANAGEMENT CO/CA/ being the largest institutional investor. By 2024-06-30, it held 13.7964% of the shares, which is about 13.66 million shares worth $12.19 million.
ARMISTICE CAPITAL, LLC, with 9.0279% or 8.94 million shares worth $7.97 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
